Previous 10 | Next 10 |
2024-01-04 09:51:10 ET More on Rhythm Pharmaceuticals Rhythm Pharmaceuticals: Major Catalysts Due For Weight Loss Specialist Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2023 Earnings Call Transcript Rhythm Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call Presentati...
-- LB54640 has shown targeted effect on MC4 receptor without hyperpigmentation -- -- Rhythm to advance LB54640 in two Phase 2 clinical trials -- BOSTON, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company...
-- Phase 3 hypothalamic obesity top-line data expected in 1H2025 -- -- Positive reimbursement decision achieved for IMCIVREE ® (setmelanotide) to treat patients with Bardet-Biedl syndrome and POMC/LEPR deficiencies in Spain -- -- IND application for RM-7...
2024-01-03 07:00:00 ET Summary The biotech industry experienced a challenging year in 2023 due to a rising 10-year Treasury yield. In 2024, the 10-year yield should favorably support biotech stocks. Promising advancements in weight loss drugs, neuroscience, oncology, and gene ...
2023-12-25 06:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
-- More than 50 poster presentations highlighting new scientific developments to advance the care of people living with rare MC4R pathway diseases -- -- Approximately 150 healthcare professionals from 20 countries expected to attend -- BOSTON, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Rhy...
-- Phase 3 trial evaluating setmelanotide in pediatric patients ages 2-<6yo (N=12) over 52 weeks achieved primary endpoint -- -- Setmelanotide achieved 3.04 mean reduction in BMI-Z score and 18.4 percent mean reduction in BMI in patients ages 2-<6yo with obesity due to POMC/LEPR def...
2023-12-04 21:29:35 ET Summary Baker Brothers' 13F portfolio value increased marginally from $17.28B to $17.35B. The largest five stakes in the portfolio are Seagen, BeiGene, Incyte, ACADIA Pharma, and BioMarin Pharma, making up approximately 86% of the portfolio. Stake increa...
2023-12-01 12:50:00 ET More on Pfizer, Rhythm Pharma etc. Pfizer Inc. (PFE) 6th Annual Evercore ISI HealthCONx Conference (Transcript) Pfizer Is A Fantastic Buy And So Are These 9%-Yielding Blue Chips Rhythm Pharmaceuticals: Major Catalysts Due For Weight Loss Specia...
2023-11-21 02:58:46 ET Summary Rhythm Pharmaceuticals' stock has experienced significant volatility, soaring and plunging multiple times since its IPO in 2017. The company's lead drug, Imcivree, was approved for chronic weight management in patients with specific genetic deficienc...
News, Short Squeeze, Breakout and More Instantly...
Rhythm Pharmaceuticals Inc. Company Name:
RYTM Stock Symbol:
NASDAQ Market:
Rhythm Pharmaceuticals Inc. Website:
BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a commercial-stage biopharmaceutical company focused on tra...
-- First quarter 2024 net revenue from global sales of IMCIVREE® (setmelanotide) of $26.0 million -- -- On track to submit sNDA to the FDA to...
Aterian Inc. (ATER) is expected to report for Q1 2024 Dorman Products Inc. (DORM) is expected to report $0.82 for Q1 2024 Hillman Solutions Corp. (HLMN) is expected to report $0.08 for Q1 2024 Wake Forest Bancshares, Inc. (WAKE) is expected to report for quarter end 2024-03-31 Inn...